Parabilis Medicines is preparing to advance its lead drug candidate, zolucatetide, into Phase 3 testing for desmoid tumors, with the company outlining plans to raise substantial funding through a proposed initial public offering to support the program and other clinical development efforts.
Zolucatetide is a Wnt/β-catenin pathway inhibitor being developed for desmoid tumors, which are rare noncancerous growths that form in connective tissue. The drug received Fast Track designation from the U.S. Food and Drug Administration for the indication in November 2025. Parabilis is now planning to launch a Phase 3 study in patients with the condition.
Beyond desmoid tumors, the company intends to continue Phase 1 studies of zolucatetide in familial adenomatous polyposis, a rare genetic disorder, as well as hepatocellular carcinoma and other solid tumors that contain Wnt pathway-activating mutations. According to company plans outlined in a regulatory filing, approximately $120 million would be allocated to these ongoing studies.
Zolucatetide is derived from Parabilis’ Helicon peptide platform. The company says these engineered peptides are designed to attach to flat surfaces that have traditionally been difficult for conventional small-molecule drugs to bind. The platform is intended to create therapies capable of reaching targets that have historically been difficult to address.
In addition to zolucatetide, Parabilis plans to invest in the advancement of other programs, including ERG, AR and β-catenin degraders. The company expects to spend approximately $130 million to move these assets into clinical testing.
To support these development activities, Parabilis has filed for an initial public offering on the Nasdaq under the ticker symbol PBLS. The biotechnology company, formerly known as FogPharma, plans to offer 25 million shares priced between $17 and $19 each. At the midpoint of that range, Parabilis estimates net proceeds of approximately $413.6 million. If underwriters fully exercise an option to purchase an additional 3.7 million shares, proceeds could reach about $476.4 million.
The planned fundraising comes shortly after a collaboration agreement with Regeneron Pharmaceuticals. Under the arrangement, Parabilis is set to receive a $50 million upfront payment and a $75 million equity investment. The companies plan to explore Parabilis’ helicons as standalone therapies and in combination with Regeneron antibodies through antibody-helicon conjugates.
Parabilis is led by Chief Executive Officer Mathai Mammen, M.D., Ph.D., the former global head of research and development at Johnson & Johnson. Speaking about his long-term goals for the company in an interview earlier this year, Mammen said, “I want to be a company that does research, development, manufactures and commercializes products.”
The company has raised significant private funding over recent years, including a $107 million Series C round in 2021, a $178 million Series D round in 2022, a $145 million Series E round in 2024, and a $305 million Series F financing completed earlier this year. Parabilis currently has 145 full-time employees and 31 full-time consultants.
Parabilis is taking a significant step forward in its oncology development strategy by preparing a Phase 3 clinical trial for Zolucatetide in patients with desmoid tumors. The announcement comes as Parabilis moves ahead with plans for an initial public offering (IPO), highlighting the company’s ambition to strengthen its position within the biotechnology sector.
The planned late-stage study represents an important milestone for Parabilis, which is focused on developing innovative therapies for patients with serious and difficult-to-treat conditions. By advancing Zolucatetide into Phase 3 testing, Parabilis aims to generate the clinical evidence necessary to support future regulatory submissions and potential commercialization.
Parabilis Expands Its Clinical Development Program
The decision to initiate a Phase 3 trial reflects growing confidence within Parabilis regarding the therapeutic potential of Zolucatetide. Earlier-stage research provided the foundation for continued development, encouraging the company to move toward a larger and more comprehensive clinical evaluation.
Market Context and Industry Significance
The biotechnology sector continues to place strong emphasis on rare disease and oncology research, where innovative therapies have the potential to address significant unmet medical needs. Desmoid tumors, although relatively rare, represent an area of growing interest because of the challenges associated with disease management and the limited number of available treatment options.
Companies that successfully develop therapies for rare conditions often benefit from regulatory incentives, expedited development opportunities, and the potential to establish leadership positions within specialized treatment markets. As a result, late-stage clinical programs in rare diseases frequently attract attention from investors, healthcare providers, and patient advocacy groups.
The Importance of Phase 3 Clinical Development
Phase 3 trials serve as one of the most critical stages in the drug development process. These studies are designed to evaluate safety and efficacy in larger patient populations and provide the evidence required for regulatory review.
Success at this stage can significantly increase the likelihood of eventual market approval, while also providing valuable information regarding long-term treatment outcomes, patient quality of life, and overall benefit-risk profiles. Regulatory agencies rely heavily on Phase 3 data when determining whether a therapy should become available to patients.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
